All PlansCoverageMedium impact
Policy Criteria Changes
Arkansas Blue Cross Blue Shield·AR · Hematology, Oncology·Medical Policy
Effective date
Nov 15, 2025
We identified it
Jun 19, 2026
Summary
Two significant drug policy changes: Kogenate (Factor VIII product) has been discontinued by the manufacturer and removed from coverage, and Prademagene Zamikeracel (Zevaskyn) is now designated as non-covered for all indications under a new policy.
Action Required
By November 15, 2025: Billing team must update drug formulary systems to remove Kogenate from available Factor VIII products and ensure Prademagene Zamikeracel (Zevaskyn) is flagged as non-covered for all indications. Update prior authorization systems and provider alerts accordingly. Claims submitted for these products after the effective date will be denied.